この作品は、公衆衛生のカリフォルニア部からNIH / NIAと07から65798からの補助金AG030709によってサポートされていました。我々は、サポートおよび試薬を提供するためのペプチドの合成とアミノ酸分析のためのマーガレットM.コンドロン、プロジェクトの最初のステップを支援し、サポートするための博士エリザベスF.ニューフェルド、博士カイ香港B.チェンを認識し、博士とアンドリューD有用な議論のため。エリントン。

<ol>
	<li>Monien, B. H., Apostolova, L. G., Bitan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Early+diagnostics+and+therapeutics+for+Alzheimer's+disease-how+early+can+we+get+there.">Early diagnostics and therapeutics for Alzheimer's disease-how early can we get there.</a> Expert. Rev. Neurother. 6, 1293-1306 (2006).</li><li>Nestor, P. J., Scheltens, P., Hodges, J. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Advances+in+the+early+detection+of+Alzheimer's+disease.">Advances in the early detection of Alzheimer's disease.</a> Nat. Med. 10, S34-S41 (2004).</li><li>Kawas, C. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Clinical+practice.+Early+Alzheimer's+disease.">Clinical practice. Early Alzheimer's disease.</a> N. Engl. J. Med. 349, 1056-1063 (2003).</li><li>Haass, C., Selkoe, D. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Soluble+protein+oligomers+in+neurodegeneration:+lessons+from+the+Alzheimer's+amyloid+&#946;-peptide.">Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid &#946;-peptide.</a> Nat. Rev. Mol. Cell. Biol. 8, 101-112 (2007).</li><li>Kirkitadze, M. D., Bitan, G., Teplow, D. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Paradigm+shifts+in+Alzheimer's+disease+and+other+neurodegenerative+disorders:+the+emerging+role+of+oligomeric+assemblies.">Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.</a> J. Neurosci. Res. 69, 567-577 (2002).</li><li>Rahimi, F., Shanmugam, A., Bitan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structure-function+relationships+of+pre-fibrillar+protein+assemblies+in+Alzheimer's+disease+and+related+disorders.">Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.</a> Curr. Alzheimer Res. 5, 319-341 (2008).</li><li>Jayasena, S. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Aptamers:+an+emerging+class+of+molecules+that+rival+antibodies+in+diagnostics.">Aptamers: an emerging class of molecules that rival antibodies in diagnostics.</a> Clin. Chem. 45, 1628-1650 (1999).</li><li>Bunka, D. H., Stockley, P. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Aptamers+come+of+age+-+at+last.">Aptamers come of age - at last.</a> Nat. Rev. Microbiol. 4, 588-596 (2006).</li><li>Ellington, A. D., Szostak, J. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=In+vitro+selection+of+RNA+molecules+that+bind+specific+ligands.">In vitro selection of RNA molecules that bind specific ligands.</a> Nature. 346, 818-822 (1990).</li><li>Tuerk, C., Gold, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Systematic+evolution+of+ligands+by+exponential+enrichment:+RNA+ligands+to+bacteriophage+T4+DNA+polymerase.">Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.</a> Science. 249, 505-510 (1990).</li><li>Lee, J. F., Stovall, G. M., Ellington, A. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Aptamer+therapeutics+advance.">Aptamer therapeutics advance.</a> Curr. Opin. Chem. Biol. 10, 282-289 (2006).</li><li>Weiss, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RNA+aptamers+specifically+interact+with+the+prion+protein+PrP.">RNA aptamers specifically interact with the prion protein PrP.</a> J. Virol. 71, 8790-8797 (1997).</li><li>Bibby, D. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Application+of+a+novel+in+vitro+selection+technique+to+isolate+and+characterise+high+affinity+DNA+aptamers+binding+mammalian+prion+proteins.">Application of a novel in vitro selection technique to isolate and characterise high affinity DNA aptamers binding mammalian prion proteins.</a> J. Virol. Methods. 151, 107-115 (2008).</li><li>Rhie, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Characterization+of+2'-fluoro-RNA+aptamers+that+bind+preferentially+to+disease-associated+conformations+of+prion+protein+and+inhibit+conversion.">Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion.</a> J. Biol. Chem. 278, 39697-39705 (2003).</li><li>King, D. J., Safar, J. G., Legname, G., Prusiner, S. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Thioaptamer+interactions+with+prion+proteins:+sequence-specific+and+non-specific+binding+sites.">Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites.</a> J. Mol. Biol. 369, 1001-1014 (2007).</li><li>Proske, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prion-protein-specific+aptamer+reduces+PrPSc+formation.">Prion-protein-specific aptamer reduces PrPSc formation.</a> ChemBioChem. 3, 717-725 (2002).</li><li>Murakami, K., Nishikawa, F., Noda, K., Yokoyama, T., Nishikawa, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Anti-bovine+prion+protein+RNA+aptamer+containing+tandem+GGA+repeat+interacts+both+with+recombinant+bovine+prion+protein+and+its+&#946;+isoform+with+high+affinity.">Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its &#946; isoform with high affinity.</a> Prion. 2, 73-80 (2008).</li><li>Luhrs, T., Zahn, R., Wuthrich, K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Amyloid+formation+by+recombinant+full-length+prion+proteins+in+phospholipid+bicelle+solutions.">Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions.</a> J. Mol. Biol. 357, 833-841 (2006).</li><li>Bunka, D. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Production+and+characterization+of+RNA+aptamers+specific+for+amyloid+fibril+epitopes.">Production and characterization of RNA aptamers specific for amyloid fibril epitopes.</a> J. Biol. Chem. 282, 34500-34509 (2007).</li><li>Ylera, F., Lurz, R., Erdmann, V. A., Furste, J. P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Selection+of+RNA+aptamers+to+the+Alzheimer's+disease+amyloid+peptide.">Selection of RNA aptamers to the Alzheimer's disease amyloid peptide.</a> Biochem. Biophys. Res. Commun. 290, 1583-1588 (2002).</li><li>Rahimi, F., Murakami, K., Summers, J. L., Chen, C. H., Bitan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RNA+aptamers+generated+against+oligomeric+A&#946;40+recognize+common+amyloid+aptatopes+with+low+specificity+but+high+sensitivity.">RNA aptamers generated against oligomeric A&#946;40 recognize common amyloid aptatopes with low specificity but high sensitivity.</a> PLoS ONE. 4, e7694-e7694 (2009).</li><li>Bitan, G., Lomakin, A., Teplow, D. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Amyloid+&#946;-protein+oligomerization:+prenucleation+interactions+revealed+by+photo-induced+cross-linking+of+unmodified+proteins.">Amyloid &#946;-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins.</a> J. Biol. Chem. 276, 35176-35184 (2001).</li><li>Rahimi, F., Maiti, P., Bitan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Photo-induced+cross-linking+of+unmodified+proteins+(PICUP)+applied+to+amyloidogenic+peptides.">Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides.</a> J. Vis. Exp. , (2009).</li><li>Bitan, G., Fradinger, E. A., Spring, S. M., Teplow, D. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Neurotoxic+protein+oligomers-what+you+see+is+not+always+what+you+get.">Neurotoxic protein oligomers-what you see is not always what you get.</a> Amyloid. 12, 88-95 (2005).</li><li>Bitan, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Structural+study+of+metastable+amyloidogenic+protein+oligomers+by+photo-induced+cross-linking+of+unmodified+proteins.">Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins.</a> Methods Enzymol. 413, 217-236 (2006).</li><li>Chen, C. H., Chernis, G. A., Hoang, V. Q., Landgraf, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inhibition+of+heregulin+signaling+by+an+aptamer+that+preferentially+binds+to+the+oligomeric+form+of+human+epidermal+growth+factor+receptor-3.">Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.</a> Proc. Natl. Acad. Sci. USA. 100, 9226-9231 (2003).</li><li>Adams, D. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Lab math: a handbook of measurements, calculations, and other quantitative skills for use at the bench. , (2003).</li><li>Gopinath, S. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Methods+developed+for+SELEX.">Methods developed for SELEX.</a> Anal. Bioanal. Chem. 387, 171-182 (2007).</li><li>Takahashi, T., Tada, K., Mihara, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=RNA+aptamers+selected+against+amyloid+&#946;-peptide+(A&#946;)+inhibit+the+aggregation+of+A&#946;.">RNA aptamers selected against amyloid &#946;-peptide (A&#946;) inhibit the aggregation of A&#946;.</a> Mol. Biosyst. 5, 986-991 (2009).</li></ol>

利害の衝突は宣言されません。

SELEXプロセスの出発点は、通常、10 12 -10 15配列を含む、ランダムオリゴヌクレオチドライブラリーの合成です。 RNA SELEXで、ここに示したのに対し、DNA SELEXでは、このライブラリは、ssDNAのプールが生成された後に直接使用され、ssDNAのライブラリは、 インビトロ転写によって酵素的にRNAのプールに最初に変換されます。各サイクルが曝露と目的のターゲットへのオリゴ...

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">	
		
		<div>
		<table border="1">
		<thead>
		<tr>
		<th>Material Name</th>
		<th>Type</th>
		<th>Company</th>
		<th>Catalogue Number</th>
		<th>Comment</th>
		</tr>
		</thead>
		<tbody>
		
<tr>
<td>A&beta;40</td>
<td>&nbsp;</td>
<td>UCLA Biopolymers Laboratory</td>
<td>&nbsp;</td>
<td>Lyophilized powder</td>
</tr>
<tr>
<td>MX5 Automated-S Microbalance</td>
<td>&nbsp;</td>
<td>Mettler Toledo</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<tr>
<td>Silicon-coated, 1.6-ml tubes</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>C19033 or C19035</td>
<td>&nbsp;</td>
<tr>
<td>1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)</td>
<td>&nbsp;</td>
<td>TCI America</td>
<td>H0424</td>
<td>Use in a fume hood.</td>
</tr>
<tr>
<td>Ammonium persulfate</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>A-7460</td>
<td>Vortex until the solution is clear. APS is prepared freshly each time and should be used within 48 h.</td>
</tr>
<tr>
<td>Tris(2,2-bipridyl)dichlororuthenium(II) hexahydrate</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>224758-1G</td>
<td>Vortex until the solution is clear. Cover the RuBpy tube with foil to protect the reagent from ambient light. RuBpy is prepared freshly each time and should be used within 48 h.</td>
</tr>
<tr>
<td>Dithiothreitol (DTT)</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>43815</td>
<td>&nbsp;</td>
<tr>
<td>D-Salt&trade; Excellulose&trade; desalting columns</td>
<td>&nbsp;</td>
<td>Thermo Scientific</td>
<td>20449</td>
<td>&nbsp;</td>
<tr>
<td>Ammonium acetate	</td>
<td>&nbsp;</td>
<td>Fisher Scientific</td>
<td>A637-500</td>
<td>&nbsp;</td>
<tr>
<td>Silicon-coated, 0.6-ml tubes</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>C19063</td>
<td>&nbsp;</td>
<tr>
<td>Novex Tricine Gels (10&#x2013;20%)</td>
<td>&nbsp;</td>
<td>Invitrogen</td>
<td>EC6625B0X</td>
<td>10-well; mini size (8 cm X 8 cm); 25 &mu;l loading volume per well; separation range 5 kDa to 40 kDa</td>
</tr>
<tr>
<td>Quartz cuvette</td>
<td>&nbsp;</td>
<td>Hellma</td>
<td>105.250-QS</td>
<td>&nbsp;</td>
<tr>
<td>Beckman DU 640 spectrophotometer</td>
<td>&nbsp;</td>
<td>Beckman</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<tr>
<td>ssDNA library</td>
<td>&nbsp;</td>
<td>Integrated DNA Technologies</td>
<td>Custom-ordered</td>
<td>The library was designed to contain 49 random nucleotides flanked by two constant regions containing primer-binding and cloning sites: 
5'-TAA TAC GAC TCA CTA TAG GGA ATT CCG CGT GTG C (N:25:25:25:25%) (N)49 G TCC GTT CGG GAT CCT C-3'</td>
</tr>
<tr>
<td>Taq DNA polymerase</td>
<td>&nbsp;</td>
<td>USB Corporation</td>
<td>71160</td>
<td>Recombinant Thermus aquaticus DNA Polymerase supplied with 10&#215; PCR Buffer and a separate tube of 25 mM MgCl2 for routine PCR.</td>
</tr>
<tr>
<td>PCR Nucleotide Mix, 10 mM solution</td>
<td>&nbsp;</td>
<td>USB Corporation</td>
<td>77212</td>
<td>(10 mM each dATP, dCTP, dGTP, dTTP)</td>
</tr>
<tr>
<td>Forward primer</td>
<td>&nbsp;</td>
<td>Integrated DNA Technologies</td>
<td>Custom-ordered</td>
<td>5'-TAA TAC GAC TCA CTA TAG GGA ATT CCG CGT GTG C-3'</td>
</tr>
<tr>
<td>Reverse primer</td>
<td>&nbsp;</td>
<td>Integrated DNA Technologies</td>
<td>Custom-ordered</td>
<td>5'-GAG GAT CCC GAA CGG AC-3'</td>
</tr>
<tr>
<td>Thermal cycler</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>Techne TC-312</td>
<td>&nbsp;</td>
<tr>
<td>QIAquick PCR Purification Kit (50)</td>
<td>&nbsp;</td>
<td>QIAGEN</td>
<td>28104</td>
<td>&nbsp;</td>
<tr>
<td>Agarose</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>CA3510-8</td>
<td>&nbsp;</td>
<tr>
<td>Conical, sterile 1.6-ml tubes with caps attached with O-rings</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>C19040-S</td>
<td>&nbsp;</td>
<tr>
<td>RiboMAX&trade; Large Scale RNA Production System&#x2013;T7</td>
<td>&nbsp;</td>
<td>Promega</td>
<td>P1300</td>
<td>The kit contains: 120 &mu;l Enzyme Mix (RNA polymerase, recombinant RNasin&reg; ribonuclease inhibitor and recombinant inorganic pyrophosphatase); 240 &mu;l transcription 5 buffer; 100 &mu;l each of 4 rNTPs, 100 mM; 110 U RQ1 RNase-free DNase, 1 U/&mu;l; 10 &mu;l linear control DNA, 1 mg/ml; 1 ml 3M sodium acetate (pH 5.2); 1.25 ml nuclease-Free water</td>
</tr>
<tr>
<td>&alpha;-32P-cytidine 5'-triphosphate, 250 &mu;Ci (9.25 MBq), </td>
<td>&nbsp;</td>
<td>Perkin Elmer</td>
<td>BLU008H250UC</td>
<td>Specific Activity: 3000 Ci (111 TBq)/mmol, 50 mM Tricine (pH 7.6)</td>
</tr>
<tr>
<td>Citrate-saturated phenol:chloroform:isoamyl alcohol (125:24:1, pH 4.7)</td>
<td>&nbsp;</td>
<td>Sigma (Fluka)</td>
<td>77619</td>
<td>&nbsp;</td>
<tr>
<td>Chloroform:Isoamyl alcohol (24:1)</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>C0549</td>
<td>&nbsp;</td>
<tr>
<td>Absolute ethanol for molecular biology</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>E7023</td>
<td>&nbsp;</td>
<tr>
<td>Z216-MK refrigerated microcentrifuge</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>C0216-MK</td>
<td>&nbsp;</td>
<tr>
<td>illustra ProbeQuant&trade; G-50 Micro Columns</td>
<td>&nbsp;</td>
<td>GE Healthcare</td>
<td>Obtained from Fisher Scientific (45-001-487)</td>
<td>Prepacked with Sephadex&trade; G-50 DNA Grade and pre-equilibrated in STE buffer containing 0.15% Kathon as Biocide</td>
</tr>
<tr>
<td>Triathler Bench-top Scintillation counter</td>
<td>&nbsp;</td>
<td>Hidex Oy, Turku, Finland</td>
<td>Triathler LSC Model: 425-034</td>
<td>&nbsp;</td>
<tr>
<td>Novex&reg; TBE-Urea Sample Buffer (2&#215;)</td>
<td>&nbsp;</td>
<td>Invitrogen</td>
<td>LC6876</td>
<td>&nbsp;</td>
<tr>
<td>6% TBE-Urea Gels 1.0 mm, 10 wells</td>
<td>&nbsp;</td>
<td>Invitrogen</td>
<td>EC6865BOX</td>
<td>&nbsp;</td>
<tr>
<td>Novex&reg; TBE Running Buffer (5&#215;)</td>
<td>&nbsp;</td>
<td>Invitrogen</td>
<td>LC6675</td>
<td>&nbsp;</td>
<tr>
<td>Radioactivity decontaminant</td>
<td>&nbsp;</td>
<td>Fisher Scientific</td>
<td>04-355-67</td>
<td>&nbsp;</td>
<tr>
<td>Gel-loading tips</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>P3080</td>
<td>&nbsp;</td>
<tr>
<td>XCell SureLock Mini-Cell</td>
<td>&nbsp;</td>
<td>Invitrogen</td>
<td>EI0001</td>
<td>XCell SureLock Mini-Cell</td>
</tr>
<tr>
<td>Autoradiography film</td>
<td>&nbsp;</td>
<td>Denville Scientific</td>
<td>E3018</td>
<td>Use in complete darkness</td>
</tr>
<tr>
<td>Autoradiography film, Hyperfilm&trade; ECL</td>
<td>&nbsp;</td>
<td>Amersham Biosciences</td>
<td>RPN3114K</td>
<td>Can be used under red safe light.</td>
</tr>
<tr>
<td>Membrane discs</td>
<td>&nbsp;</td>
<td>Millipore</td>
<td>GSWP02500</td>
<td>Mixed cellulose ester, hydrophilic, 0.22-&mu;m disc membranes</td>
</tr>
<tr>
<td>Fritted glass support base for 125-ml flask</td>
<td>&nbsp;</td>
<td>VWR</td>
<td>26316-696</td>
<td>&nbsp;</td>
<tr>
<td>Petri dishes</td>
<td>&nbsp;</td>
<td>Fisher Scientific</td>
<td>08-757-11YZ</td>
<td>&nbsp;</td>
<tr>
<td>Urea	</td>
<td>&nbsp;</td>
<td>Fisher Scientific</td>
<td>AC32738-0050</td>
<td>&nbsp;</td>
<tr>
<td>EDTA</td>
<td>&nbsp;</td>
<td>Fisher Scientific</td>
<td>118430010</td>
<td>&nbsp;</td>
<tr>
<td>Glycogen</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>G1767</td>
<td>&nbsp;</td>
<tr>
<td>2-Propanol for molecular biology</td>
<td>&nbsp;</td>
<td>Sigma</td>
<td>I9516</td>
<td>&nbsp;</td>
<tr>
<td>Recombinant RNase inhibitor</td>
<td>&nbsp;</td>
<td>USB Corporation</td>
<td>71571</td>
<td>&nbsp;</td>
<tr>
<td>ImProm-II&trade;Reverse Transcription System</td>
<td>&nbsp;</td>
<td>Promega</td>
<td>A3802</td>
<td>&nbsp;</td>
<tr>
<td>Recombinant RNase inhibitor</td>
<td>&nbsp;</td>
<td>USB Corporation</td>
<td>71571</td>
<td>&nbsp;</td>
<tr>
<td>RapidRun&trade; Loading Dye</td>
<td>&nbsp;</td>
<td>USB Corporation</td>
<td>77524</td>
<td>&nbsp;</td>		</tbody>
		</table>
		</div>

selection of aptamers for amyloid &beta;-protein, the causative agent of alzheimer&#39;s disease

アルツハイマー病（AD）は1、その発症前診断が困難なレンダリング狡猾なコースを持つプログレッシブ、年齢依存性、神経変性疾患である。明確なADの診断は、このように、ADの発症前、早期診断が効果的な治療法2,3の開発と管理のための非常に重要である確立する、唯一の事後分析を実現しています。 アミロイドβ-蛋白質は（Aβ）ADの病因の中心です。水溶性、オリゴマーAβアセンブリはAD 4,5におけるシナプス機能障害とニューロンの損失の基礎となる神経毒性に影響を及ぼすと考えられている。可溶性Aβアセンブリの様々な形態が記載されている、しかし、それらの相互関係と、ADの病因および病因に関連性は複雑で、ウェル6理解されていない。症状が現れる前に、特定の分子認識ツールでは、Aβアセンブリ間の関係を解明し、疾患の過程で早期にこれらのアセンブリの検出と特徴付けを促進することができる。分子認識は、一般的に抗体に依存しています。しかし、分子認識ツールの代替クラス、アプタマーは、抗体7,8の相対重要な利点を提供しています。指数関数的濃縮（SELEX）9,10によるリガンドの系統進化：アプタマーは、 試験管内の選択によって生成されたオリゴヌクレオチドである。 SELEXは、ダーウィンの進化論に似て、可能にする、という反復的なプロセスであり、選択、増幅、濃縮、およびプロパティの永続化、など、熱心な、特定の、リガンド結合（アプタマー）または触媒活性（リボザイムとDNAzymes）。 現代のバイオテクノロジーと医学11のツールとしてのアプタマーの出現にもかかわらず、彼らはアミロイドの分野で十分に活用されています。いくつかのRNAまたはssDNAのアプタマーは、プリオン蛋白質（プリオン）12月16日の様々な形態に対して選択されています。組換えウシのPrPに対して生成されたRNAアプタマーは、アミロイド線維の18を形成する完全長のPrPの水溶性、オリゴマー、β-シートが豊富な立体配座の変異型、ウシのPrP -β17を認識することが示された。アプタマーは、線維のβ2 -ミクログロブリン（β2 m）の単量体といくつかの形式を使用して生成されたβ2メートルフィブリル19に加えて、特定の他のアミロイドタンパク質の線維を結合することが見出された。 Ylera ら 。固定化単量体のAβ4020に対して選択されたRNAアプタマーを説明した。不意に、これらのアプタマーは、線維Aβ40をバインド。完全に、これらのデータはいくつかの重要な問題を提起する。なぜ単量体のタンパク質に対して選択されたアプタマーは、それらのポリマー形態を認識するのですか？アミロイド生成性タンパク質の単量体及び/またはオリゴマーの形態に対するアプタマーが得られるか？これらの質問に対処するために、我々は、光誘起架橋無修正のタンパク質（PICUP）22,23を使用して生成された共有結合で安定化オリゴマーAβ4021のアプタマーを選択することを試みた。前回の調査結果17,19,20と同様に、これらのアプタマーは、おそらく構造aptatope 21潜在的に共通のアミロイドを認識Aβおよび他のいくつかのアミロイド蛋白質の線維と反応した。ここで、我々は、これらのアプタマー21の製造に使用されるSELEX方法論を提示する。

Watch this Scientific Journal Video about Selection of Aptamers for Amyloid Î²-Protein, the Causative Agent of Alzheimer's Disease at JoVE.com

Selection of Aptamers for Amyloid &amp;#946;-Protein, the Causative Agent of Alzheimer&#039;s Disease

アプタマーは、で選択された短いribo-/deoxyribo-oligonucleotidesです<em&gt;体外</em&gt;特定のターゲットの親和性に基づく進化の方法。アプタマーは、多目的な治療、診断、および研究アプリケーションとの分子認識ツールです。我々は、アミロイドβ-蛋白質、アルツハイマー病の原因物質のためのアプタマーの選択のための方法を示しています。

アミロイドβ-蛋白質、アルツハイマー病の原因物質のためのアプタマーの選択

Alzheimer's disease (AD) is a progressive, age-dependent, neurodegenerative disorder with an insidious course that renders its presymptomatic diagnosis ...

selection-aptamers-for-amyloid-protein-causative-agent-alzheimer-s

Research

JoVE Journal

Neuroscience

Selection of Aptamers for Amyloid &beta;-Protein, the Causative Agent of Alzheimer&#39;s Disease

19.3K ビュー.  David Geffen School of Medicine. アプタマーは、で選択された短いribo-/deoxyribo-oligonucleotidesです体外特定のターゲットの親和性に基づく進化の方法。アプタマーは、多目的な治療、診断、および研究アプリケーションとの分子認識ツールです。我々は、アミロイドβ-蛋白質、アルツハイマー病の原因物質のためのアプタマーの選択のための方法を示しています。